Golden Age Resources (GDAR) Enters the Highly Profitable Pharmaceutical Business with New Management and a Potential Licensing Deal with Biopharma Pravo Alpha

Licensing Deal to Add Six Prescription Products with over 20 Billion dollars in Potential market size to GDAR Pipeline

PALM BEACH GARDENS, FL–(Marketwired – May 4, 2016) – Golden Age Resources Inc. (OTC PINK: GDAR), a leading acquisition and development company, announced today that it entered the highly profitable pharmaceutical business with the signing of a term sheet with Biopharma Pravo alpha for the perpetual exclusive worldwide rights for six products for a potential of 20 billion dollar markets. Under the terms of the signed term sheet, GDAR will have an exclusive perpetual pre-paid worldwide rights for the following products focusing on cardiovascular, anti-microbial, immunity and pain relief:

Product

API

Indication

Potential Market Size (USD)

Nitrosorbid

Isosorbide Dinitrate

A vasodilator used in the treatment of angina pectoris

>3B Worldwide

Ampicillin Trihydrate

Ampicillin Trihydrate

Antibiotic-Penniclin

~500M wordlwide

Analgin

Metamizole

Pain releif

~30M (EU is ~7-10M currently

Corvalol (Корвалол, Corvalolum, Korvalol)

• Ethyl ester of α- bromoisovaleric acid (ethyl 2-bromo-3- methylbutyrate)
• Phenobarbital
• Peppermint oil

Neuroses with heightened irritability/Insomnia/As a part of complex treatment of hypertension/Non-acute spasm of coronary vessels/Tachycardia/Gastrointestinal cramping (as a spasmolytic agent)

~20-30M

Tubosan

tebuconazol

ImmunoStimulator

~10M

Lovastatin

Lovastatin

Treatment of dyslipidemia and the prevention of cardiovascular disease: lowering cholesterol (hypolipidemic agent)

>20B

 

The Company expects to close the licensing deal in the upcoming weeks and will continue to update its shareholders on the progress.

In connection with the change in direction, the Company announced the appointment of Mr. Daniel Kogan as the new President & Chief Executive Officer effective immediately. Mr. Kogan replaces Mr. Byrne who decided to pursue other opportunities. The Company would like to thank Mr. Byrne for his contributions and wish him good luck with his new endeavors.

“I am delighted to join GDAR as its President & CEO to build the new management team and execute on the Board’s new direction to move the Company into the commercial stage and a positive cash flow situation in the near future” Said Mr. Kogan.

“Once we complete the licensing agreement of the new products and start receiving approvals in the different territories, we expect to move to a cash flow positive situation very fast and turn the corner to profitability” continued Mr. Kogan.

Prior to GDAR, Mr. Kogan held management positions at Metlife (NYSE: MET) and KOSH. He has extensive experience in finance, management and merger and acquisitions. Mr. Kogan holds an MBA from St. John’s University / Peter J. Tobin College of Business.

About Golden Age Resources, Inc.

Headquartered in Pam Beach Gardens, GDAR plans to focus on the development of prescription and over the counter medicines in large therapeutics areas including, cardiovascular, anti- microbial, immunity, arthritis and pain among others.

For more information visit http://www.gdarinc.com

 

About Biopharma Pravo Alpha (BPA)

Biopharma Bravo Alpha (BBA) is a 15 year old Russian based fully integrated pharma leader in innovative and generic pharmaceuticals. The Company’s vertical integration gives it the needed stability in a dynamic supply and business environment. The company has 15 drugs currently commercialized in Russia with Tubosan® to increase immunity as the lead product. In addition, the Company has an impressive pipeline of products at various stages of approval.

For more information visit http://www.alphabiopharma.com